

1                                    **European Autism GENomics Registry (EAGER):**  
2                                    **Protocol for a multicentre cohort study and registry**

3

4    **Authors:**

5    Bloomfield, M.<sup>1\*</sup>, Lautarescu, A.<sup>1\*</sup>, Heraty, S.<sup>2</sup>, Douglas, S.<sup>3</sup>, Violland, P.<sup>3</sup>, Plas, R.<sup>3</sup>, Ghosh,  
6    A.<sup>3</sup>, Van den Bosch, K.<sup>3</sup>, Eaton, E.<sup>4</sup>, Absoud, M.<sup>5,6</sup>, Battini, R.<sup>7,8</sup>, Blázquez Hinojosa, A.<sup>9</sup>,  
7    Bolshakova, N.<sup>10</sup>, Bolte, S.<sup>11,12,13</sup>, Bonanni, P.<sup>14</sup>, Borg, J.<sup>15,16</sup>, Calderoni, S.<sup>7,8</sup>, Calvo  
8    Escalona, R.<sup>9,17,18,19</sup>, Castelo-Branco, M.<sup>20</sup>, Castro-Fornieles, J.<sup>9,17,18,19</sup>, Caro P.<sup>21</sup>, Danieli,  
9    A.<sup>14</sup>, Delorme, R.<sup>22</sup>, Elia, M.<sup>23</sup>, Hempel, M.<sup>21</sup>, Madeira, N.<sup>24,25,26</sup>, McAlonan, G.<sup>27,28</sup>, Milone,  
10   R.<sup>7</sup>, Molloy, C. J.<sup>10</sup>, Mougá, S.<sup>29,30</sup>, Montiel, V.<sup>31</sup>, Pina Rodrigues, A.<sup>29,30</sup>, Schaaf, C. P.<sup>21</sup>,  
11   Serrano, M.<sup>31</sup>, Tammimies, K.<sup>11,32</sup>, Tye, C.<sup>1</sup>, Vigevano, F.<sup>33</sup>, Oliveira, G.<sup>34,35</sup>, Mazzone, B.<sup>7</sup>,  
12   O'Neill, C.<sup>36</sup>, Romero, V.<sup>37</sup>, Tillmann, J.<sup>38</sup>, Oakley, B.<sup>27</sup>, Murphy, D.<sup>27,39,40</sup>, Gallagher,  
13   L.<sup>10,41,42,43</sup>, Bourgeron, T.<sup>44</sup>, Chatham, C.<sup>45</sup>, Charman, T.<sup>1</sup>

14    \* Indicates equal contribution

15

16    **Affiliations:**

17    1 - Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's  
18    College London, London, United Kingdom

19    2 - Department of Psychological Sciences, University of London, Birkbeck, London, United  
20    Kingdom

21    3 - AIMS-2-Trials A-Reps, University of Cambridge, Cambridge, United Kingdom

22    4 - Autism Research Centre, University of Cambridge, Cambridge, United Kingdom

- 23 5 - Department of Children's Neurosciences, Evelina London Children's Hospital, Guy's and  
24 St Thomas' NHS Foundation Trust, London, United Kingdom
- 25 6 - Department of Women and Children's Health, Faculty of Life Sciences and Medicine,  
26 School of Life Course Sciences, King's College London, London, United Kingdom
- 27 7 - Department of Developmental Neuroscience, IRCCS, Fondazione Stella Maris, Pisa, Italy
- 28 8 - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 29 9 - Department of Child and Adolescent Psychiatry and Psychology, Institute of  
30 Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- 31 10 - Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
- 32 11 - Center of Neurodevelopmental Disorders (KIND), Department of Women's and  
33 Children's Health, Centre for Psychiatry Research, Karolinska Institutet & Region Stockholm,  
34 Stockholm, Sweden
- 35 12 - Child and Adolescent Psychiatry, Stockholm Health Care Services, Region Stockholm,  
36 Stockholm, Sweden
- 37 13 - Curtin Autism Research Group, Curtin School of Allied Health, Curtin University, Perth,  
38 Australia
- 39 14 - Epilepsy Unit, Scientific Institute IRCCS E. Medea Conegliano, Treviso, Italy
- 40 15 - Centre for Psychiatry Research and Centre for Cognitive and Computational  
41 Neuropsychiatry (CCNP), Department of Clinical Neuroscience, Karolinska Institutet &  
42 Stockholm Health Care Services, Region Stockholm, Sweden
- 43 16 - Psykiatri Affektiva, Sahlgrenska University Hospital, Gothenburg, Sweden
- 44 17 - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- 45 18 - Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain

- 46 19 - Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona,  
47 Spain
- 48 20 - CIBIT, ICNAS, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 49 21 - Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
- 50 22 - Child and Adolescent Psychiatry Department, Robert Debre Hospital, APHP, Université  
51 Paris Cité, Paris, France
- 52 23 - Unit of Neurology and Clinical Neurophysiopathology, Oasi Research Institute-IRCCS,  
53 Troina, Italy
- 54 24 - Psychiatry Department, Centro Hospitalar e Universitário de Coimbra, Coimbra,  
55 Portugal
- 56 25 - Coimbra Institute for Biomedical Imaging and Translational Research, University of  
57 Coimbra, Coimbra, Portugal
- 58 26 - Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra,  
59 Coimbra, Portugal
- 60 27 – Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry,  
61 Psychology & Neuroscience, King's College London, London, United Kingdom
- 62 28 - Behavioural and Developmental Clinical Academic Group, South London and Maudsley  
63 NHS Foundation Trust, London, United Kingdom
- 64 29 - CIBIT - Coimbra Institute for Biomedical Imaging and Translational Research, University  
65 of Coimbra, Coimbra, Portugal
- 66 30 - ICNAS - Institute of Nuclear Sciences Applied to Health, University of Coimbra,  
67 Coimbra, Portugal
- 68 31 - Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant  
69 Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

- 70 32 - Astrid Lindgren Children's Hospital, Karolinska University Hospital, Region Stockholm,  
71 Stockholm, Sweden
- 72 33 - Neurological Sciences and Rehabilitation Medicine Scientific Area - Bambino Gesù  
73 Children's Hospital, Rome, Italy
- 74 34 – University Clinic of Pediatrics, Faculty of Medicine, University of Coimbra, 3000-602  
75 Coimbra, Portugal
- 76 35 - Child Developmental Center and Research and Clinical Training Center, Pediatric  
77 Hospital, Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-602 Coimbra, Portugal
- 78 36 - Cure Sanfilippo Foundation
- 79 37 - Dup15q Alliance
- 80 38 - Roche Pharma Research and Early Development, Roche Innovation Center Basel,  
81 Basel, Switzerland
- 82 39 - South London and Maudsley NHS Foundation Trust (SLaM), London SE5 8AZ, UK
- 83 40 - Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology &  
84 Neuroscience, King's College London, London WC2R 2LS, UK
- 85 41 - Department of Psychiatry at The Hospital for Sick Children
- 86 42 - Child and Youth Division Centre for Addiction and Mental Health, CAMH
- 87 43 - Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto
- 88 44 - Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS,  
89 Université de Paris Cité, IUF, Paris, France
- 90 45 - F. Hoffman-La Roche Ltd, Basel, Switzerland
- 91
- 92

93 **Corresponding author**

94 Dr Alexandra Lautarescu, Department of Psychology, Institute of Psychiatry, Psychology &  
95 Neuroscience, King's College London, [Alexandra.Lautarescu@kcl.ac.uk](mailto:Alexandra.Lautarescu@kcl.ac.uk)

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114 **ABSTRACT**

115 **Introduction:** Autism is a common neurodevelopmental condition with a complex genetic  
116 aetiology that includes contributions from monogenic and polygenic factors. Many autistic  
117 people have unmet healthcare needs that could be served by genomics-informed research  
118 and clinical trials. The primary aim of the European Autism GENomics Registry (EAGER) is  
119 to establish a registry of participants with a diagnosis of autism or an associated rare genetic  
120 condition who have undergone whole-genome sequencing. The registry can facilitate  
121 recruitment for future clinical trials and research studies, based on genetic, clinical, and  
122 phenotypic profiles, as well as participant preferences. The secondary aim of EAGER is to  
123 investigate the association between mental and physical health characteristics and  
124 participants' genetic profiles.

125 **Methods and analysis:** EAGER is a European multisite cohort study and registry and is part  
126 of the AIMS-2-TRIALS consortium. EAGER was developed with input from the AIMS-2-  
127 TRIALS Autism Representatives and representatives from the rare genetic conditions  
128 community. 1,500 participants with a diagnosis of autism or an associated rare genetic  
129 condition will be recruited at 13 sites across 8 countries. Participants will give a blood or  
130 saliva sample for whole-genome sequencing and answer a series of online questionnaires.  
131 Participants may also consent for the study to access pre-existing clinical data. Participants  
132 will be added to the EAGER registry. Data will be shared via the Autism Sharing Initiative, a  
133 new international collaboration aiming to create a federated system for autism data sharing.

134 **Ethics and dissemination:** EAGER has received full ethical approval from ethics  
135 committees in the UK (REC 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023)  
136 and Spain (HCB/2023/0038, PIC-164-22). Approvals are in the process of being obtained  
137 from committees in Italy, Sweden, Ireland, and France. Findings will be disseminated via  
138 scientific publications and conferences, but also beyond to participants and the wider  
139 community (e.g., the AIMS-2-TRIALS website, stakeholder meetings, newsletters).

140

141 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 142 • Data from full genotyping through whole-genome sequencing will be combined with  
143 mental and physical health data and participant research priorities
- 144 • The EAGER sample (n=1,500), although relatively small for genetic analyses, will include  
145 a substantial proportion (around one third) of participants with a rare genetic condition,  
146 ensuring that heterogeneous presentations across the autism spectrum are captured
- 147 • The EAGER registry will improve the speed, efficiency, and impact of research studies  
148 and clinical trials across Europe with a culturally diverse cohort of re-contactable  
149 participants, and shared data through the Autism Sharing Initiative
- 150 • EAGER was developed with input from the AIMS-2-TRIALS Autism Representatives and  
151 representatives from the rare genetic conditions community
- 152 • Phenotypic data are collected only via self/informant-report questionnaires and not direct  
153 clinical assessments

154

155

156

157

158

159

160

161

162

163        **1. INTRODUCTION**

164

165        Autism is a neurodevelopmental condition diagnosed on the basis of differences in social  
166        communication and interaction, sensory processing, restricted and repetitive behaviours,  
167        and intense interests (1,2), with a prevalence of around 1-2% of the general population (3).  
168        Autism is associated with a very large number of common genetic variants of small effect  
169        (4), as well as being associated with several rare genetic conditions such as Dup15q  
170        syndrome, Rett syndrome, tuberous sclerosis complex, and Angelman syndrome, where  
171        autism prevalence is as high as 30-93% (5,6).

172

173        Many autistic people have co-occurring mental and physical health conditions that impact  
174        quality of life, such as depression, anxiety, gastrointestinal symptoms, and epilepsy (7–12).  
175        For some autistic people and those with associated rare genetic conditions, many of these  
176        conditions can be severe and life-limiting, including respiratory and cardiac disorders in Rett  
177        syndrome (13,14), hyperphagia in Prader-Willi syndrome (15), and tumour growth in  
178        tuberous sclerosis complex (16). This makes the development of treatments and support for  
179        these populations a crucial area of research. Further, some autistic people may find aspects  
180        of being autistic distressing and disabling and may want help with these (17–20). All autistic  
181        people have the right to evidence-based care and support for aspects that are detrimental to  
182        their quality of life and wellbeing (21). Despite this, there is currently a paucity of  
183        personalised evidence-based care and support for autistic people across the spectrum  
184        (22,23), and polypharmacy (i.e., taking multiple medications) for various co-occurring  
185        symptoms is commonplace (24).

186



187 With a heritability of around 80%, autism has strong genetic influences (e.g., 25,26).  
188 However, to date, there is no known gene that, when mutated, increases the likelihood of an  
189 autism diagnosis without also increasing the likelihood of intellectual disability or other  
190 neurodevelopmental conditions (27). Consequently, genetic research is an important  
191 biomedical tool in the study of autism and associated rare genetic conditions, with benefits  
192 including personalised medicine, early identification of health risks, a better self-  
193 understanding, and a sense of community (28). To aid the development of evidence-based  
194 care for autistic people and those with associated rare genetic conditions, it is crucial to  
195 better understand genetic differences between syndromic forms of autism and autism  
196 without a known highly penetrant genetic influence. Further, by linking genetic mechanisms  
197 to treatment outcomes, autistic people and those with associated rare genetic conditions can  
198 be offered accurate information about what difficulties they may face both presently and in  
199 the future, and what interventions may be effective for aspects of their lived experience that  
200 they want or need support with.

201

202 EAGER (European Autism GEnomics Registry) is a European multicentre study that aims to  
203 create a registry of 1,500 participants with a diagnosis of autism or a rare genetic condition  
204 associated with autism. Participants will give a biosample and whole-genome sequencing  
205 will be performed on extracted DNA; participants will also answer a series of questionnaires  
206 related to autism, quality of life, mental and physical health, and research preferences. Using  
207 extensive genetic and phenotypic data, EAGER will enable a better understanding of the  
208 genetic architecture of autism and associated rare genetic conditions, as well as the  
209 relationship between genetics and outcomes such as health, quality of life, and wellbeing.

210

211 The EAGER registry will allow participants to be recontacted for future research studies or  
212 clinical trials that may be suitable for them. This will facilitate research by streamlining and

213 accelerating recruitment across Europe, as well as bring together key research and clinical  
214 institutions, to the benefit of participants and their families. In line with tailoring evidence-  
215 based care to specific populations, clinical trials that are genetically-informed allow  
216 researchers to invite participants who are the most suited to, and may benefit most from, a  
217 treatment (29). Selective recruitment at the early stages of treatment development  
218 encourages the downstream development of personalised medicine.

219

220 This project aims to be a catalyst for future research and clinical trials in autism and  
221 associated rare genetic conditions in Europe. This will be achieved by connecting key sites  
222 and allowing research groups and pharmaceutical companies planning research studies or  
223 clinical trials to have access to a European registry of people who have consented to being  
224 recontacted. EAGER data will also be shared via the Autism Sharing Initiative (ASI), a global  
225 collaboration connecting autism data through federated mechanisms (30). The genetic,  
226 phenotypic, and clinical data collected in EAGER can therefore be analysed with other  
227 international autism datasets such as MSSNG (31), POND (32), LEAP (33), SPARK (34),  
228 and Searchlight (35), providing the opportunity to investigate key research questions.

229

230

231

232

233

234

235

236

237 **2. METHODS AND ANALYSIS**


238

239 **2.1. Study design and population**

240 EAGER is an international, multisite registry of adults and children with a diagnosis of autism  
 241 or associated rare genetic conditions. Recruitment for EAGER will take place at 13 sites  
 242 across 8 European countries (see figure 1).

243

244 *Figure 1. EAGER collaborating centres*



245

246

247 To be eligible, participants need to be over 2 years of age and have a diagnosed rare  
 248 genetic condition associated with autism and/or have a diagnosis of autism (see figure 2).

249 Decisions regarding which conditions and genetic variants to include have been made on the

250 basis of published literature (36) and discussions with experts in the field (TB, LG), with  
251 consideration given to the penetrance, prevalence, and association with autism. For  
252 participants with a diagnosis of autism only, and where existing genetic information is  
253 available, recruitment will prioritise individuals within multiplex families and individuals with  
254 genetic variants associated with autism (see figure 2). Participants will not be excluded from  
255 the study based on any other characteristics such as co-occurring conditions, sex, or  
256 intellectual disability.

257

258

259

260

261

262

263

264

265

266

267

268


269

270

271

272

273 Figure 2. EAGER protocol summary



275           **2.2. Patient and public involvement and ethical consultations**

276 Genetic research can involve complex ethical challenges, making it crucial to prioritise  
277 ethical considerations and participatory research practices (21,28). Participatory research  
278 practices can help ensure that the interests of our participants are appropriately represented  
279 and that the study is beneficial to its participants and the wider community. EAGER was  
280 developed with crucial input and feedback from community representatives via dedicated  
281 working groups. Our autism working group consists of AIMS-2-TRIALS Autism  
282 Representatives: autistic people and family members or carers of autistic people. Our rare  
283 genetic conditions working group consists of parents/carers of people with rare genetic  
284 conditions and/or representatives from European rare genetic conditions associations. As  
285 EAGER was conceptualised and funded prior to the establishment of our lived experience  
286 working groups, it is not a fully participatory research endeavour. This was discussed with  
287 and understood by all members of the working groups at the outset of our collaboration.  
288 Within these constraints, every effort was made to consult with our lived experience partners  
289 throughout the lifespan of this project, and feedback was integrated to the greatest degree  
290 possible.

291

292 The EAGER working groups have offered invaluable advice and feedback to guide the  
293 planning process of EAGER (see Box 1), either as part of working group meetings or  
294 through communication via email or contributions to collaborative documents. Open  
295 discussion within these groups was encouraged; as the groups included a variety of  
296 perspectives, there were naturally different solutions to questions. When no consensus was  
297 reached, the core research team made the final decision based on feasibility.

298

299

300

301 *Box 1. Key examples of how patient and public involvement guided the EAGER study*

- Refining the study rationale and clarifying perceived benefit of the study for autistic people
- Deciding on study name and logo
- Discussing ethical implications of the research, ensuring that appropriate safeguards are in place and that any limitations are transparently communicated to participants
- Ensuring that the information presented in study documents is clear, accessible, transparent, and sufficient to allow participants to make an informed decision about their participation
- Creating a “Data sharing Frequently Asked Questions” document to accompany the information sheet
- Developing different versions of information sheets tailored to the needs of our different participant groups (e.g., easy-read, adolescent information sheet)
- Ensuring that the consent forms are clear and transparent about what precisely a participant is consenting to
- Ensuring that the language used in study documents is appropriate and in line with community preferences
- Discussing the phenotypic measures used in the study and suggesting changes to the content/language of questionnaires
- Sharing all key study documents for feedback prior to submission for ethical approval
- Clearly stating that EAGER is against eugenics / prenatal testing for autism on participant-facing documents
- Detailing exactly what analyses will be performed on participant data and making it clear that no further analyses will occur without reconsenting
- Clarifying that analyses performed on EAGER data will need to be approved by a committee before they can begin
- Clarifying in the ethics documents that not all decisions were made based on consensus
- Adding a disclaimer in the protocol/ethics with regards to the fact that citing papers does not represent an endorsement of the language/aims of those papers or of the authors

302

303 Further, we conducted consultation with other stakeholders, ethical advisors, and additional  
304 working groups within the consortium, in order to evaluate risks and potentially sensitive  
305 implications of this research. We hope that the aforementioned groups will guide EAGER in  
306 the most beneficial direction for its participants and the wider community. These groups will  
307 continue to be consulted throughout the lifetime of the project.

308

309

### 310 **2.3. Participant recruitment, information sheets, and informed consent**

311 Potential participants will be approached by representatives at each local site. Each site will  
312 screen and recruit participants based upon recontact of participants from prior research  
313 studies or prior/current patients that fit the inclusion criteria.

314

315 Written informed consent will be required for participation in the study and participants will be  
316 provided with information sheets tailored to their age and levels of intellectual disability (see  
317 figure 2 for details on documents for specific participant groups). A personal consultee will  
318 be asked to consent on behalf of individuals who are deemed to not have capacity to  
319 consent following a capacity to consent assessment. Due to the high prevalence of co-  
320 occurring intellectual disability in people with rare genetic conditions, these may make up a  
321 significant proportion of the overall sample. Parental consent will be required for those under  
322 the legal age of consent (e.g., 16 years old in the UK).

323

324 To take part in EAGER, participants must consent to core aspects of the study: giving a  
325 blood or saliva sample (or permission to use a pre-existing sample), completing  
326 questionnaires, being added to the registry, and data sharing.

327



328        **2.4.    Biological sample collection**

329    Participants will give a blood or saliva sample, depending on preference and  
330    appropriateness. The Oragene<sup>®</sup>•DNA self-collection kits, as well as assisted collection kits  
331    for those unable to collect their own sample, will be used for saliva collection. If existing  
332    blood or saliva samples are available and have been stored appropriately, they can be used  
333    in lieu of a new sample, with participant consent.

334

335        **2.5.    Measures**

336    Following collection of the biological sample, participants will be given access to an online  
337    form with a series of questionnaires, focussing on autism, rare genetic conditions, co-  
338    occurring physical and mental health conditions, opinions on research priorities, and quality  
339    of life and wellbeing (see table 1). These will be a mixture of validated and non-validated  
340    questionnaires that have been adapted for EAGER, and have been chosen to overlap with  
341    other major initiatives or studies both within AIMS-2-TRIALS (37,38) and externally, such as  
342    MSSNG (31), POND (32), LEAP (33), SPARK (34), and Simon’s Searchlight (35). All  
343    questionnaires have been translated into the local language of each site from English. The  
344    online questionnaires will be completed by participants answering on behalf of themselves,  
345    or by parents and consultees answering on behalf of the participant.

346

347

348

349

350

351

352 *Table 1. EAGER questionnaires*

<b>Domain</b>	<b>Measure</b>	<b>Description</b>	<b>Respondents</b>
<b>Autism traits</b>	Social Responsiveness Scale (SRS (39))	65 items: Autism traits (including social awareness, cognition, communication, motivation, and repetitive interests and behaviours)	Adult self-report
	Social Communication Questionnaire (SCQ, (40))	40 items: Autism traits (including communication skills and social functioning)	Parent or consultee report for child or adult
<b>Mental health</b>	Strengths and Difficulties Questionnaire (SDQ, (41))	25 items: General mental health across five scales (conduct problems, hyperactivity, emotional problems, peer problems, prosocial behaviour)	Parent or consultee report for adult or child
	Patient Health Questionnaire-9 (PHQ-9, (42))	9 items: Core features of major depressive disorder	Adult self-report
	Patient Health Questionnaire-A (PHQ-A, (43))	9 items: Core features of major depressive disorder*	Adolescent (16 and 17 years) self-report
	Generalised Anxiety Disorder-7 (GAD-7, (44))	7 items: Core features of generalised anxiety disorder	Adult self-report
<b>Quality of life</b>	World Health Organization Quality of Life-BREF (WHO-QOL-BREF, (45))	26 items: Quality of life across four domains (physical health, psychological health, social relationships, environment)	Adult self-report
	Cantrill Ladder (46)	1 item: Subjective quality of life (10 point scale from “worst possible life” to “best possible life”)	Adult self-report. Parent or consultee report for child or adult.
<b>Mental wellbeing</b>	Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS,	14 items: Mental wellbeing and health	Adult self-report. Parent or consultee

	(47))		self-report <sup>+</sup>
<b>Restrictive and repetitive behaviours</b>	Adult Routines inventory (ARI, (48))  Repetitive Behaviours Scale-Revised (RBS-R, (49))	55 items: Restrictive and repetitive behaviours  43: Assessing restrictive and repetitive behaviours	Adult self-report  Parent or consultee report for child or adult
<b>ADHD</b>	Conners' Adult ADHD Rating Scales (CAARS, (50))  ADHD Rating Scale (51))	26 items: Core features of ADHD  18 items: Core features of ADHD	Adult self-report  Parent report for child Consultee report for adult <sup>^</sup>
<b>Demographics</b>	Non-validated questionnaire	16-25 items: Demographic characteristics	Adult self-report. Parent or consultee report for child or adult.
<b>Co-occurring conditions</b>	Non-validated questionnaire (adapted from Simons Searchlight (35))	Items assessing 168 diagnosed and self-diagnosed psychiatric, neurodevelopmental, and physical health conditions.	Adult self-report. Parent or consultee report for child or adult.
<b>Medications</b>	Non-validated questionnaire	1 item: Number of medications taken by participant per day	Adult self-report. Parent or consultee report for child or adult.
<b>General functioning</b>	Non-validated questionnaire (adapted from (52))	7-11 items: Seizures, gross motor skills, language and communication, intellectual disability, support needs, sleep	Adult self-report. Parent or consultee report for child or adult.
<b>Voice of the community</b>	Non-validated questionnaire (adapted from Simon	7-13 items: Priorities for research	Adult self-report. Parent or consultee

	Searchlight (35))		report for child or adult.
--	-------------------	--	----------------------------

353 \* Additional questions and assessment of suicidality in the original measure were removed for the purpose of this study and  
354 only the first core 9 items were included.

355 ^ The ADHD rating scale was adapted for use in EAGER to make it appropriate for adults and remove child-specific language.

356 \* Administered to parents and caregivers in relation to their own mental wellbeing.

357

358

## 359 **2.6. Data analysis**

360 EAGER will collect genetic and phenotypic data, which can be analysed both alone and in

361 conjunction with other data collected within AIMS-2-TRIALS and/or shared via the ASI.

362 Research questions will be decided in collaboration with our community working groups.

363 Examples include identifying genetic variants that are associated with aspects of the core

364 autism phenotype or conditions such as epilepsy or major depressive disorder, and

365 identifying the association between genetic variants and/or polygenic scores and traits such

366 as quality of life, levels of cognitive ability and executive function. The sample size of this

367 study (n=1,500), which was driven by the available budget, is moderate-to-large in the field

368 and will be significantly enhanced via the planned data sharing and integration.

369

370

371

372

373

374

375

## 376 **3. DATA SHARING AND EAGER REGISTRY**

377

### 378 **3.1. Data sharing**

379 Currently, funding bodies and participant groups have identified the need for research  
380 groups to share their data to maximise the value of each research contribution, pool data to  
381 address research questions that require a larger number of participants, or to carry out meta-  
382 analyses (53). For this reason, EAGER data will be shared via established AIMS-2-TRIALS  
383 data sharing mechanisms as well as being directly implemented into the ASI as detailed  
384 below. Rigorous safeguards will be implemented for access to data via established AIMS-2-  
385 TRIALS mechanisms and via the ASI platform (30).

386

387 Researchers will not be able to access EAGER data without approval from a data access  
388 committee, which will consist of autistic and non-autistic people, researchers, and members  
389 of the rare genetic community.

390

#### 391 *3.1.1. Autism Sharing Initiative (ASI)*

392 The ASI is a new collaboration working to create the first federated, global network for  
393 sharing genomic and clinical data in autism research. The ASI is led by software company  
394 DNASTack and involves other collaborators such as Autism Speaks, Roche, and the Ontario  
395 Brain Institute (please see (54) for the full list). This is an ongoing project and new  
396 collaborators may be added.

397

398 Data sharing within the ASI will be built upon decentralised, federated data sharing  
399 principles. Data federation allows researchers to search, access, and analyse data that  
400 reside in different locations and are connected via a network, without the need for data to be  
401 moved between institutions/researchers.

402

403 Data federation allows researchers to interrogate and analyse data hosted in different  
404 locations, in compliance with data regulations and improving privacy and security. A  
405 federated data network involves connecting individual datasets, which remain in their  
406 protected local environments (i.e., at the research institution where the data was collected),  
407 across one cloud-based network. To our knowledge, the ASI carries no additional risk to  
408 participant re-identification than traditional data sharing. The ASI software is built upon  
409 security standards developed by the Global Alliance for Genomics and Health (55), and  
410 regularly updated in order to ensure that data are safeguarded.

411

412 Within the ASI, data will include genomic, multi-omic, medical, and clinical data from  
413 international autism research sources. With participant consent, EAGER data (genetic data,  
414 data from online questionnaires, and existing data held at local sites) will be shared through  
415 the ASI platform with any explicit identifiers removed.

416

### 417 **3.2. EAGER registry**

418 The EAGER registry will allow participants to be contacted for future clinical trials and  
419 research studies. Researchers viewing shared participant data will be able to contact the  
420 coordinating site (King's College London) to request specific participant groups based upon  
421 their desired criteria without access to participant personal information. King's College  
422 London will pass these requests onto the relevant local sites, who can send information  
423 about the study or clinical trial to participants.

424

## 425 **4. ETHICS AND DISSEMINATION**

426

427 **4.1. Ethics**

428 EAGER has received full ethical approval from ethics committees in the UK (REC  
429 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023) and Spain (HCB/2023/0038,  
430 PIC-164-22). Approvals are in the process of being obtained from ethics committees in Italy,  
431 Sweden, Ireland, and France. Please refer to the above section “Patient and Public  
432 Involvement and Ethics Consultation” for detail on ethics and discussions within our  
433 community working groups.

434

435 **4.2. Dissemination**

436 We plan to disseminate our findings widely via academic avenues, such as publications in  
437 peer-reviewed major international scientific journals and conferences. In addition, we will  
438 disseminate beyond academic avenues to ensure that our findings reach participants and  
439 the wider communities, including the AIMS-2-TRIALS website ([www.aims2trials.eu](http://www.aims2trials.eu)),  
440 stakeholder meetings, and newsletters. As part of the overall AIMS-2-TRIALS project, we  
441 have access to a European network including researchers, clinicians, and families within the  
442 autism community. This network will also provide a forum for dissemination of research  
443 findings and training opportunities.

444

445 *Disclaimer: Citing papers does not represent an endorsement of the language used in these*  
446 *papers, nor of the aims of the research or researchers.*

447

448

449 **REFERENCES**

- 450 1. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum  
451 disorder. *Nat Rev Dis Primers*. 2020 Jan 16;6(1):1–23.
- 452 2. Kodak T, Bergmann S. Autism Spectrum Disorder: Characteristics, Associated  
453 Behaviors, and Early Intervention. *Pediatr Clin North Am*. 2020 Jun;67(3):525–35.
- 454 3. Zeidan J, Fombonne E, Scora J, Ibrahim A, Durkin MS, Saxena S, et al. Global  
455 prevalence of autism: A systematic review update. *Autism Res*. 2022 May;15(5):778–90.
- 456 4. Willsey HR, Willsey AJ, Wang B, State MW. Genomics, convergent neuroscience and  
457 progress in understanding autism spectrum disorder. *Nat Rev Neurosci*. 2022  
458 Jun;23(6):323–41.
- 459 5. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum  
460 disorder phenomenology in genetic disorders: a systematic review and meta-analysis.  
461 *The Lancet Psychiatry*. 2015 Oct 1;2(10):909–16.
- 462 6. Lusk L, Vogel-Farley V, DiStefano C, Jeste S. Maternal 15q Duplication Syndrome. In:  
463 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors.  
464 *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited  
465 2022 May 9]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK367946/>
- 466 7. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-  
467 occurring mental health diagnoses in the autism population: a systematic review and  
468 meta-analysis. *Lancet Psychiatry*. 2019 Oct;6(10):819–29.
- 469 8. Tye C, Runicles AK, Whitehouse AJO, Alvares GA. Characterizing the Interplay  
470 Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative  
471 Review. *Front Psychiatry*. 2018;9:751.



- 472 9. van Heijst BF, Deserno MK, Rhebergen D, Geurts HM. Autism and depression are  
473 connected: A report of two complimentary network studies. *Autism*. 2020 Apr;24(3):680–  
474 92.
- 475 10. Hollocks MJ, Lerh JW, Magiati I, Meiser-Stedman R, Brugha TS. Anxiety and depression  
476 in adults with autism spectrum disorder: a systematic review and meta-analysis.  
477 *Psychological Medicine*. 2019 Mar;49(4):559–72.
- 478 11. Wang J, Ma B, Wang J, Zhang Z, Chen O. Global prevalence of autism spectrum  
479 disorder and its gastrointestinal symptoms: A systematic review and meta-analysis.  
480 *Front Psychiatry*. 2022 Aug 23;13:963102.
- 481 12. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges.  
482 *Neuropsychiatr Dis Treat*. 2017 Dec 18;14:1–10.
- 483 13. Acampa M, Guideri F. Cardiac disease and Rett syndrome. *Arch Dis Child*. 2006  
484 May;91(5):440–3.
- 485 14. Katz DM, Dutschmann M, Ramirez JM, Hilaire G. Breathing Disorders in Rett Syndrome:  
486 Progressive Neurochemical Dysfunction in the Respiratory Network after Birth. *Respir*  
487 *Physiol Neurobiol*. 2009 Aug 31;168(1–2):101–8.
- 488 15. Driscoll DJ, Miller JL, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Mirzaa GM,  
489 Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. *GeneReviews®* [Internet].  
490 Seattle (WA): University of Washington, Seattle; 1993 [cited 2023 Sep 18]. Available  
491 from: <http://www.ncbi.nlm.nih.gov/books/NBK1330/>
- 492 16. Islam MP. Tuberous Sclerosis Complex. *Semin Pediatr Neurol*. 2021 Apr;37:100875.
- 493 17. Schaaf RC, Toth-Cohen S, Johnson SL, Outten G, Benevides TW. The everyday  
494 routines of families of children with autism: examining the impact of sensory processing  
495 difficulties on the family. *Autism*. 2011 May;15(3):373–89.

- 496 18. Green D, Chandler S, Charman T, Simonoff E, Baird G. Brief Report: DSM-5 Sensory  
497 Behaviours in Children With and Without an Autism Spectrum Disorder. *J Autism Dev*  
498 *Disord.* 2016 Nov 1;46(11):3597–606.
- 499 19. Lai MC, Anagnostou E, Wiznitzer M, Allison C, Baron-Cohen S. Evidence-based support  
500 for autistic people across the lifespan: maximising potential, minimising barriers, and  
501 optimising the person-environment fit. *Lancet Neurol.* 2020 May;19(5):434–51.
- 502 20. Lord C, Charman T, Havdahl A, Carbone P, Anagnostou E, Boyd B, et al. The Lancet  
503 Commission on the future of care and clinical research in autism. *The Lancet.* 2022  
504 Jan;399(10321):271–334.
- 505 21. Heraty S, Lautarescu A, Belton D, Boyle A, Cirrincione P, Doherty M, et al. Bridge-  
506 building between communities: Imagining the future of biomedical autism research. *Cell.*  
507 2023 Aug 31;186(18):3747–52.
- 508 22. Sandbank M, Bottema-Beutel K, Crowley S, Cassidy M, Dunham K, Feldman JI, et al.  
509 Project AIM: Autism intervention meta-analysis for studies of young children.  
510 *Psychological Bulletin.* 2020;146(1):1–29.
- 511 23. Braga LAM, Conte Filho CG, Mota FB. Future of genetic therapies for rare genetic  
512 diseases: what to expect for the next 15 years? *Ther Adv Rare Dis.* 2022 Jun  
513 10;3:26330040221100840.
- 514 24. Feroe AG, Uppal N, Gutiérrez-Sacristán A, Mousavi S, Greenspun P, Surati R, et al.  
515 Medication Use in the Management of Comorbidities Among Individuals With Autism  
516 Spectrum Disorder From a Large Nationwide Insurance Database. *JAMA Pediatrics.*  
517 2021 Sep 1;175(9):957–65.

- 518 25. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of  
519 Genetic and Environmental Factors With Autism in a 5-Country Cohort. *JAMA*  
520 *Psychiatry*. 2019 Oct 1;76(10):1035–43.
- 521 26. Tick B, Bolton P, Happé F, Rutter M, Rijdsdijk F. Heritability of autism spectrum disorders:  
522 a meta-analysis of twin studies. *Journal of Child Psychology and Psychiatry*.  
523 2016;57(5):585–95.
- 524 27. Myers SM, Challman TD, Bernier R, Bourgeron T, Chung WK, Constantino JN, et al.  
525 Insufficient Evidence for “Autism-Specific” Genes. *Am J Hum Genet*. 2020 May  
526 7;106(5):587–95.
- 527 28. Natri HM, Chapman CR, Heraty S, Dwyer P, Walker N, Kapp SK, et al. Ethical  
528 challenges in autism genomics: Recommendations for researchers. *European Journal of*  
529 *Medical Genetics*. 2023 Sep 1;66(9):104810.
- 530 29. Díaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marín O, Bagni C, et al. A  
531 white paper on a neurodevelopmental framework for drug discovery in autism and other  
532 neurodevelopmental disorders. *Eur Neuropsychopharmacol*. 2021 Jul;48:49–88.
- 533 30. DNASTack [Internet]. [cited 2023 Oct 8]. DNASTack launches Neuroscience AI to  
534 accelerate collaborative research and discovery, DNASTack. Available from:  
535 <https://dnastack.com/news-neuroscience-ai-launch-announcement/>
- 536 31. MSSNG [Internet]. [cited 2023 Sep 18]. Available from: <https://research.mss.ng/>
- 537 32. POND. Your Research Priorities [Internet]. Province of Ontario Neurodevelopmental  
538 Network. [cited 2023 Apr 11]. Available from: [https://pond-network.ca/your-research-](https://pond-network.ca/your-research-priorities/)  
539 [priorities/](https://pond-network.ca/your-research-priorities/)

- 540 33. Charman T, Loth E, Tillmann J, Crawley D, Wooldridge C, Goyard D, et al. The EU-  
541 AIMS Longitudinal European Autism Project (LEAP): clinical characterisation. *Molecular*  
542 *Autism*. 2017 Jun 23;8(1):27.
- 543 34. SPARK [Internet]. [cited 2023 Sep 18]. Available from: <https://sparkforautism.org/>
- 544 35. SFARI [Internet]. 2019 [cited 2023 Sep 18]. SFARI | Simons Searchlight. Available from:  
545 <https://www.sfari.org/resource/simons-searchlight/>
- 546 36. Rolland T, Cliquet F, Anney RJL, Moreau C, Traut N, Mathieu A, et al. Phenotypic  
547 effects of genetic variants associated with autism. *Nat Med*. 2023 Jul;29(7):1671–80.
- 548 37. AIMS-2-TRIALS - Autism Research For Europe [Internet]. 2018 [cited 2023 Oct 8].  
549 Available from: <https://www.aims-2-trials.eu/>
- 550 38. Oakley BFM, Loth E, Jones EJH, Chatham CH, Murphy DG. Advances in the  
551 identification and validation of autism biomarkers. *Nat Rev Drug Discov*. 2022  
552 Oct;21(10):697–8.
- 553 39. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al.  
554 Validation of a Brief Quantitative Measure of Autistic Traits: Comparison of the Social  
555 Responsiveness Scale with the Autism Diagnostic Interview-Revised. *J Autism Dev*  
556 *Disord*. 2003 Aug 1;33(4):427–33.
- 557 40. (SCQ) Social Communication Questionnaire [Internet]. [cited 2023 Sep 18]. Available  
558 from: <https://www.wpspublish.com/scq-social-communication-questionnaire.html>
- 559 41. Goodman R. The Strengths and Difficulties Questionnaire: a research note. *J Child*  
560 *Psychol Psychiatry*. 1997 Jul;38(5):581–6.
- 561 42. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity  
562 measure. *J Gen Intern Med*. 2001 Sep;16(9):606–13.

- 563 43. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for  
564 adolescents: validation of an instrument for the assessment of mental disorders among  
565 adolescent primary care patients. *J Adolesc Health*. 2002 Mar;30(3):196–204.
- 566 44. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing  
567 Generalized Anxiety Disorder: The GAD-7. *Archives of Internal Medicine*. 2006 May  
568 22;166(10):1092–7.
- 569 45. WHOQOL - Measuring Quality of Life| The World Health Organization [Internet]. [cited  
570 2023 Sep 18]. Available from: <https://www.who.int/tools/whoqol>
- 571 46. Cantril H. The pattern of human concerns. New Brunswick, N.J.: Rutgers University  
572 Press; 1966. 427 p.
- 573 47. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-  
574 Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. *Health  
575 and Quality of Life Outcomes*. 2007 Nov 27;5(1):63.
- 576 48. Evans DW, Uljarević M, Lusk LG, Loth E, Frazier T. Development of Two Dimensional  
577 Measures of Restricted and Repetitive Behavior in Parents and Children. *Journal of the  
578 American Academy of Child & Adolescent Psychiatry*. 2017 Jan 1;56(1):51–8.
- 579 49. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Repetitive Behavior Scale—Revised  
580 [Internet]. 2014 [cited 2023 Sep 18]. Available from:  
581 <http://doi.apa.org/getdoi.cfm?doi=10.1037/t17338-000>
- 582 50. Macey KD. Conners' Adult ADHD Rating Scales (CAARS). *Archives of Clinical  
583 Neuropsychology*. 2003 May 1;18(4):431–7.
- 584 51. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale—IV: Checklists,  
585 norms, and clinical interpretation. New York, NY, US: The Guilford Press; 1998. viii, 79  
586 p. (ADHD Rating Scale—IV: Checklists, norms, and clinical interpretation).

- 587 52. Keute M, Miller MT, Krishnan ML, Sadhwani A, Chamberlain S, Thibert RL, et al.  
588 Angelman syndrome genotypes manifest varying degrees of clinical severity and  
589 developmental impairment. *Mol Psychiatry*. 2021 Jul;26(7):3625–33.
- 590 53. Lombardo MV, Lai MC, Baron-Cohen S. Big data approaches to decomposing  
591 heterogeneity across the autism spectrum. *Mol Psychiatry*. 2019 Oct;24(10):1435–50.
- 592 54. Digital Supercluster [Internet]. [cited 2023 Oct 8]. Autism Sharing Initiative. Available  
593 from: <https://www.digitalsupercluster.ca/projects/autism-sharing-initiative/>
- 594 55. Global Alliance for Genomics and Health. Enabling responsible genomic data sharing for  
595 the benefit of human health [Internet]. 2023 [cited 2023 Apr 11]. Available from:  
596 <https://www.ga4gh.org/>

597

598

599 **AUTHOR CONTRIBUTIONS:**

600 **Conceptualisation:** MB, AL, SH, SD, PV, RP, AG, KVdB, EE, CO, VR, JT, BO, DM, LG,  
601 TB, CC, TC. **Funding acquisition:** DM, CC, TC. **Project administration:** MB, AL, DM, LG,  
602 TB, CC, TC. **Supervision:** AL, TC. **Visualisation:** MB, AL. **Data collection:** MB, AL, MA,  
603 RB, ABH, NB, SB, PB, JB, SC, RCE, MCB, JCF, PC, AD, RD, ME, MH, NM, GM, RM, CJM,  
604 SM, VM, APR, CPS, MS, KT, CT, FV, GO, BM, LG, TC. **Writing - original draft:** MB, AL,  
605 TC. **Writing - review and editing:** All authors

606

607 **FUNDING STATEMENT:**

608 This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking  
609 under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking  
610 receives support from the European Union's Horizon 2020 research and innovation

611 programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI and from Horizon Europe  
612 [grant agreement no. 101057385] and from Horizon Europe [grant agreement no.  
613 101057385] and from UK Research and Innovation (UKRI) under the UK government's  
614 Horizon Europe funding guarantee [grant no.10039383] (R2D2-MH). The funders had no  
615 role in the design of the study; in the collection, analyses, or interpretation of data; in the  
616 writing of the manuscript, or in the decision to publish the results. Any views expressed are  
617 those of the author(s) and not necessarily those of the funders. In addition, SB receives  
618 funding from Swedish Research Council and Region Stockholm. CT receives funding from  
619 Epilepsy Research UK, Autistica, the Baily Thomas Charitable Fund and the Tuberous  
620 Sclerosis Association. LG receives funding from Horizon Europe: Risk and Resilience in  
621 Developmental Diversity and Mental Health (R2D2-MH). CPS receives funding from  
622 Foundation of Prader-Willi Research, European Joint Program for Rare Diseases, Illumina,  
623 German Children's Cancer Foundation, and the German Ministry of Education and  
624 Research. RB, RM, SC, BM receive funding from the Italian Ministry of Health (Ricerca  
625 Corrente and 5x1000 to IRCCS Fondazione Stella Maris). Genomic data utilised here will be  
626 sequenced in part/whole through the financial contribution of F Hoffmann La-Roche. This  
627 paper represents independent research part-funded by the NIHR Maudsley Biomedical  
628 Research Centre at South London and Maudsley NHS Foundation Trust and King's College  
629 London. The views expressed are those of the author(s) and not necessarily those of the  
630 NIHR or the Department of Health and Social Care.

631

632 **COMPETING INTEREST STATEMENT:**

633 In the past 3 years TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and  
634 Servier and has received royalties from Sage Publications and Guilford Publications. DM has  
635 received funding for a PhD studentship from Compass, and for consulting from Jaguar  
636 Therapeutics and Hoffman Le Roche. GM receives funding for an investigator-initiated study  
637 from Compass Pathways; no financial or other conflict of interest with the present study. SB

638 discloses that he has in the last 3 years acted as an author, consultant, or lecturer for  
639 Medice, Roche, and Linus Biotechnology. SB receives royalties for textbooks and diagnostic  
640 tools from Hogrefe, UTB, Ernst Reinhardt, Kohlhammer, and Liber, and is a partner at  
641 NeuroSupportSolutions International AB. CC is a full-time employee of Genentech and owns  
642 stocks or RSUs in Roche Holdings, Ltd. MA is the UK chief investigator for a trial sponsored  
643 by Roche (a phase II, randomised, double-blind, placebo-controlled, parallel group study to  
644 evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of treatment with  
645 basmasanil in participants aged 2 to 14 years old with dup15q syndrome followed by a 2-  
646 year optional open-label extension). LB served on an advisory board to Kingdom  
647 therapeutics in 2022.

648

649 **WORD COUNT: 2418**